Sage Journals: Discover world-class research

Abstract

Introduction:

Despite the high cannabis use rates among sexual minority (SM) individuals, less research has examined factors related to cannabis use among SM (vs. heterosexual) individuals, especially in places with legal medical cannabis retail markets and high structural stigma, like Oklahoma.

Methods:

Data were from a survey of Oklahoma adults, including 3020 females (18.6% SM) and 2279 males (10.1% SM). Bivariate analyses examined associations of sexual identity with cannabis-related factors (i.e., perceived harm, positive attitudes, marketing exposure, depressive symptoms, anxiety symptoms) and cannabis use and use severity (i.e., past 30-day use, daily/near-daily use, cannabis use disorder [CUD] symptoms). Logistic regression examined associations of sexual identity and cannabis-related factors with cannabis use and use severity among females and males, separately.

Results:

SM (vs. heterosexual) females reported greater odds of past 30-day cannabis use and daily/near-daily use, lower harm perceptions, greater marketing exposure, and higher rates of depressive/anxiety symptoms. Lower harm perceptions and greater marketing exposure were associated with greater odds of past 30-day use, whereas marketing exposure was associated with greater odds of daily/near-daily use. SM (vs. heterosexual) males reported greater odds of daily/near-daily use and higher rates of depressive/anxiety symptoms.

Conclusions:

SM (vs. heterosexual) females reported higher rates of cannabis use, whereas SM (vs. heterosexual) females and males reported higher rates of daily/near-daily cannabis use. Potential targets for cannabis-related health campaigns aimed at reducing use differences include correcting misinterpretations of harm that may emanate from cannabis marketing efforts among females and addressing depressive symptoms among males.

Keywords

sexual minority cannabis use harm perceptions marketing exposure mental health

Highlights

Sexual minority (vs. heterosexual) females displayed greater odds of any past 30-day cannabis use.

Sexual minority (vs. heterosexual) females and males displayed greater odds of daily/near-daily cannabis use.

Among sexual minority females, findings may be related to cannabis marketing exposure and harm perceptions.

Among sexual minority males, findings may be related to depressive symptoms.

Introduction

Cannabis is the most commonly used federally illicit substance among US adults, with current use rates doubling from 7% in 2013 to 16% in 2022.¹ Although cannabis may have medical utility when used appropriately (e.g., treating chronic pain),² unintended public health consequences may occur. Cannabis use (defined as any cannabis use, more frequent cannabis use, or cannabis use disorder [CUD] across studies) is associated with motor vehicle crashes, mental health problems, and use of other substances (e.g., tobacco, alcohol).^2,3 Moreover, individuals may develop CUD, which has behavioral, social, and psychological ramifications.^4,5

Certain minoritized individuals, including those identifying as a sexual minority (SM; i.e., gay/lesbian, bisexual, or another nonheterosexual identity) person, display higher rates of cannabis use relative to heterosexual individuals.^6
-12 In 2018, 37.6% of SM adults reported past-year cannabis use, relative to 16.2% of heterosexual adults.^13,14 Some findings suggest important differences in cannabis use with regard to sex (i.e., sex assigned at birth)^9,15 and gender (i.e., current gender identity),¹⁶ with the association between sexual identity and any past 30-day cannabis use being stronger for females^9,15 and women¹⁶ relative to males^9,15 and men.¹⁶ SM individuals also are more likely to meet criteria for CUD (i.e., continued use of cannabis despite significant impairment¹⁷)¹⁰ and are more likely to engage in daily cannabis use⁸ relative to heterosexual individuals.

The prevailing explanation for substance use differences among SM, relative to heterosexual people is based on Minority Stress Theory, which suggests that SM individuals face stressors (e.g., discrimination) as a result of the stigmatization of their minoritized sexual identity.^18,19 This stress is theorized to increase mental health symptoms (e.g., depression, anxiety) and deplete coping resources, which may lead to increased coping-related substance use.²⁰ A growing body of literature has linked SM stressors (e.g., discrimination,^21,22 structural stigma,²³ social rejection²⁴) to differences in past-year cannabis use,²³ past 30-day use,^24,25 and higher CUD rates.^21,22

Research is sparse regarding other factors that may contribute to cannabis use among SM individuals. Cannabis-related perceptions (e.g., perceived harm to health) and marketing exposure may also contribute to cannabis use differences. SM (vs. heterosexual) individuals report lower levels of perceived harm to health related to cannabis use,²⁶ which is related to a greater likelihood of past 30-day cannabis use among adults, broadly.^27
-33 Regarding cannabis marketing exposure, research has primarily focused on adolescents and young adults and suggests that SM individuals report greater exposure to cannabis marketing (via magazine/newspaper, storefront, online, billboards/signs), but this work did not assess the role of exposure on cannabis use.^34,35 However, cannabis marketing exposure is associated with increased odds of current cannabis use among individuals, generally.^36
-41

Cannabis use may be especially prevalent among SM individuals residing in Oklahoma, where there is greater stigma toward SM individuals, potentially leading to greater mental health symptoms and in turn, cannabis use.⁴² Moreover, Oklahoma legalized medical cannabis in 2018 and has the second-most cannabis dispensaries per capita relative to any other state.⁴³ Thus, SM individuals residing in Oklahoma may be commonly exposed to cannabis marketing and have positive perceptions regarding cannabis (which is associated with greater marketing exposure⁴⁴), further contributing to elevated rates of cannabis use.

Although elevated rates of cannabis use among SM individuals are evident, less is known about the range of factors that may be associated with cannabis use and use severity among SM, relative to heterosexual adults. Moreover, research on SM cannabis use is lacking in places with legal cannabis retail markets, high structural stigma, and pronounced SM substance use, like Oklahoma.^45,46 This work is critical to inform public health efforts aimed at reducing cannabis use among this vulnerable population, particularly as further cannabis legalization across the United States is likely.⁴⁷ To identify factors associated with differences in cannabis use among SM versus heterosexual individuals, the current study examined associations between sexual identity and potential cannabis-related factors (i.e., perceived harm to health, positive cannabis perceptions, cannabis marketing exposure, depressive symptoms, anxiety symptoms). We then examined associations of sexual identity and these cannabis-related factors with cannabis use and use severity (i.e., any past 30-day use, daily/near-daily use, CUD symptoms). Based on the aforementioned literature, we hypothesized that SM (vs. heterosexual) individuals would display greater odds for current cannabis use, daily/near-daily cannabis use, and CUD symptoms. Moreover, SM (vs. heterosexual) individuals were expected to report lower cannabis-related harm perceptions and greater positive attitudes toward cannabis; a greater proportion of SM individuals was expected to report cannabis marketing exposure, depressive symptoms, and anxiety symptoms. Lower harm perceptions, greater positive attitudes, marketing exposure, and depressive and anxiety symptoms were hypothesized to predict greater odds of each cannabis-related outcome.

Methods

Participants and Procedures

Participants were adults (≥18 years old) living in Oklahoma (verified by self-reported zip code). Potentially eligible individuals in the Lucid Marketplace were sent a study invitation, and those who passed the initial screening and provided consent were eligible to complete the survey. A total of 5394 participants completed the survey. The sample was closely aligned with the racial and ethnic demographics of Oklahoma (i.e., 75.3% White, 8.9% Black, 0.4% Native Hawaiian or Pacific Islander, 8.4% American Indian or Alaskan Native, 5.6% more than one race, 9.5% Hispanic).⁴⁸ There was a higher proportion of female participants relative to the state population (56.8% vs. 50.1%).⁴⁸ The median household income of study participants was $30 000 to $39 999, compared with a median income of $56,956 among Oklahomans, and 92.7% of participants reported completing high school/GED, compared with 88.7% of Oklahomans.⁴⁸ Participants were compensated based on incentives provided by the panel to which they belonged (e.g., cash, gift cards, points to redeem reward prizes or gift cards; equating to roughly $1). Our final analytic sample included 5299 adults with data on sexual identity. Procedures were approved by the Site University of Oklahoma Health Sciences Center IRB.

Measures

Covariates

Participants reported their age, race (White, Black/African American, Asian, Native Hawaiian/Other Pacific Islander, American Indian/Alaskan Native, more than one race), ethnicity, income (≤$19,999, $20,000-$39,999, $40,000-$59,999, $60,000-$79,999, $80,000-$99,999, ≥$100,000), employment status (full time, part-time, unemployed and looking for work, unemployed and not looking for work, homemaker, student, retired, unable to work or disabled, other), education (less than bachelor’s degree and more than bachelor’s degree), health insurance (i.e., Medicare, Medicaid, Military/Veteran’s, private, no insurance), and whether they had a medical cannabis license (yes/no) issued by the Oklahoma Medical Marijuana Authority. Age at first cannabis use was assessed by asking participants to indicate their age when they first tried cannabis.

Sexual Identity by Sex Subgroup

Participants were asked, “Do you consider yourself: straight/heterosexual, lesbian or gay, bisexual, transgender, another sexual identity, questioning, queer, don’t know/not sure, refuse to answer?” The transgender response option was excluded from analyses due to the small sample size (n = 4 females, n = 6 males) and because it was included only at Wave 1. Participants who declined to report their sexual identity (n = 3 females, n = 4 males) were coded as missing and excluded from the analyses. Participants were categorized as straight/heterosexual or SM (lesbian/gay, bisexual, another sexual identity, questioning, queer, do not know/not sure aggregated). Regarding sex, participants were asked, “What is your biological sex: male, female?”

Cannabis-Related Factors

Participants reported on cannabis-related perceptions, cannabis marketing exposure, and mental health symptoms. Cannabis harm perceptions were assessed by asking, “How much do you think people harm themselves when they use cannabis?” on a 4-point scale (1 = no harm to 4 = a lot of harm). Positive attitudes toward cannabis use were assessed with 3 items: (1) cannabis is not addictive; (2) cannabis is safer to use than prescribed pain medications; and (3) cannabis is an effective treatment for general health conditions, on a 5-point scale (0 = strongly disagree to 4 = strongly agree; α = 0.80). Responses were averaged with higher scores indicating more positive attitudes.

To assess cannabis marketing exposure, participants were asked whether they saw each of the following in the past 30 days: (1) ads or promotions (e.g., billboards, posters) for a cannabis dispensary; (2) social media user-generated content related to cannabis products; (3) ads or promotions for cannabis products or dispensaries when reading a newspaper or magazine; and (4) ads or promotions for cannabis products when using the Internet (α = 0.74). Participants were classified as reporting any (vs. no) cannabis marketing exposure in the past 30 days if they endorsed seeing at least one marketing source.

Participants completed the Patient Health Questionnaire (PHQ-2),⁴⁹ which includes two items assessing depressive symptoms and the Generalized Anxiety Disorder (GAD-2) Questionnaire,⁵⁰ which includes 2 items assessing anxiety symptoms. Participants were asked, “Over the last 2 weeks, how often have you been bothered by the following problems: little interest of pleasure in doing things; feeling down, depressed, or hopeless; feeling nervous, anxious, or on edge; and not being able to stop or control worrying” on a four-point scale (1 = not at all to 4 = nearly every day). Responses to the first two items were summed to create a total depressive symptoms (α = 0.84) score, and responses to the last two items were summed to create a total anxiety symptoms (α = 0.88) score. Individuals who received a score at or above the cutoff (≥3) were coded as experiencing depressive or anxiety symptoms, respectively.

Cannabis Use and Use Severity

Participants indicated the number of days they used cannabis in the past 30 days (0-30). Those who reported using ≥1 day were classified as having used cannabis in the past 30 days. Among those who reported past 30-day cannabis use, we created a variable indicating daily/near-daily cannabis use (yes/no to using ≥20 of the past 30 days).⁵¹ Participants who reported past 30-day use completed the three-item Cannabis Use Disorder Identification Test—Short form (CUDIT-SF) to assess CUD symptoms (α = 0.76).¹⁷ CUDIT-SF scores range from 0 to 12 with scores ≥2 indicating a positive screen for CUD and <2 indicating a negative screen.

Data Analysis

Analyses were conducted among females (n = 3,020) and males (n = 2,279) separately using SPSS v29 (Released 2022; IBM Corp.). Bivariate analyses (i.e., chi-square tests, independent samples t-tests) examined associations between sexual identity and covariates (i.e., age, race/ethnicity, income, employment, education, health insurance, medical cannabis license, age at first cannabis use), cannabis-related factors (i.e., cannabis harm perceptions, positive attitudes, cannabis marketing exposure, mental health symptoms), and cannabis use and use severity (i.e., past 30-day cannabis use, daily/near-daily use, CUD symptoms). Crude (i.e., including sexual identity only) and adjusted (i.e., including sexual identity, cannabis-related factors, and covariates) logistic regression models examined associations of sexual identity and cannabis-related factors with odds of: (1) past 30-day cannabis use; (2) daily/near-daily cannabis use; and (3) CUD symptoms, controlling for sociodemographic variables (selected based on prior literature^2,44,52
-57 and preliminary analyses indicating associations between selected covariates and outcome variables at P < 0.05). Thus, three crude and three adjusted multinomial logistic regression models were run for females and males, respectively. Missing data comprised ≤5% of all analyses; participants with missing data were excluded from analyses (Little’s test for missingness completely at random: Ps > 0.05).

Results

Cannabis-Related Factors and Cannabis Use Among Females

Among females, 18.6% identified as SM, 81.4% as heterosexual, and 33.5% reported past 30-day cannabis use (Table 1). A greater percentage of SM (vs. heterosexual) females were younger, racially and ethnically diverse (i.e., non-Hispanic other race, Hispanic), reported lower income (i.e., less than $20 000), were unemployed, uninsured, and had a medical cannabis license. A lower percentage of SM females reported having at least a bachelor’s degree. Additionally, SM females initiated cannabis use at a younger age. In terms of cannabis-related factors, SM (vs. heterosexual) females reported lower cannabis harm perceptions. A greater percentage of SM (vs. heterosexual) females reported cannabis marketing exposure, depressive symptoms, anxiety symptoms, past 30-day cannabis use and daily/near-daily cannabis use.

Table 1.

Participant Characteristics and Bivariate Analyses Examining Differences Between Females Identifying as Sexual Minority Versus Heterosexual, N = 3020.

Variables	Total, N = 3020 (100.0%)	Sexual minority, N = 561 (18.6%)	Heterosexual, N = 2459 (81.4%)	χ²/t-statistic	P
Covariates
Age, n (%)	—	—	—	290.82	<0.001
18-24	673 (22.3)	247 (44.0)	426 (17.3)	—	—
25-34	669 (22.2)	160 (28.5)	509 (20.7)	—	—
35-44	525 (17.4)	89 (15.9)	436 (17.7)	—	—
45-54	460 (15.2)	38 (6.8)	422 (17.2)	—	—
55-64	401 (13.3)	15 (2.7)	386 (15.7)	—	—
65+	292 (9.7)	12 (2.1)	280 (11.4)	—	—
Race/ethnicity, n (%)	—	—	—	40.92	<0.001
NH White	2153 (71.3)	340 (60.7)	1813 (73.7)	—	—
NH Black	224 (7.4)	52 (9.3)	172 (7.0)	—	—
NH, another race^a	394 (13.1)	96 (17.1)	298 (12.1)	—	—
Hispanic	248 (8.2)	72 (12.9)	176 (7.2)	—	—
Income, n (%)	—	—	—	30.61	<0.001
Less than $20 000	875 (30.7)	203 (39.2)	672 (28.8)	—	—
$20 000-$49 999	1052 (36.9)	187 (36.2)	865 (37.0)	—	—
$50 000-$99 999	690 (24.2)	104 (20.1)	586 (25.1)	—	—
$100 000+	235 (8.2)	23 (4.4)	212 (9.1)	—	—
Employment, n (%)	—	—	—	25.39	<0.001
Employed full/part-time	1389 (46.0)	251 (44.7)	1138 (46.3)	—
Unemployed	424 (14.0)	115 (20.5)	309 (12.6)	—
Other	1207 (40.0)	195 (34.8)	1012 (41.2)	—
More than bachelor’s degree, n (%)	696 (23.1)	90 (16.0)	606 (24.7)	19.09	<0.001
Health insurance, n (%)	—	—	—	7.02	0.030
Private	1169 (38.7)	193 (34.4)	976 (39.7)	—	—
Government^b	1196 (39.6)	228 (40.6)	968 (39.4)	—	—
No insurance	653 (21.6)	140 (25.0)	513 (20.9)	—	—
Medical cannabis license, n (%)	626 (20.7)	178 (31.7)	448 (18.2)	50.74	<0.001
Age of first cannabis use, M (SD)	18.44 (7.94)	16.57 (5.31)	18.98 (8.49)	5.32	<0.001
Cannabis-related factors
Harm perceptions of cannabis use,^c M (SD)	1.81 (0.97)	1.56 (0.82)	1.87 (0.98)	6.97	<0.001
Positive attitudes toward cannabis,^d M (SD)	3.37 (1.03)	3.64 (1.00)	3.31 (1.03)	−6.81	0.625
Any cannabis marketing exposure, n (%)	2226 (73.8)	432 (77.1)	1794 (73.1)	3.91	0.048
Depressive symptoms, n (%)	870 (28.8)	241 (43.0)	629 (25.6)	67.08	<0.001
Anxiety symptoms, n (%)	978(32.4)	247 (44.1)	731 (29.8)	42.73	<0.001
Cannabis use and use severity
Any past 30-day use, n (%)	985 (33.5)	288 (53.0)	697 (29.1)	113.51	<0.001
Among individuals reporting past 30-day use (n = 985)
Daily/near-daily use, n (%)	494 (50.2)	170 (59.0)	324 (46.5)	12.83	<0.001
CUD symptoms, n (%)	424 (43.0)	136 (47.2)	288 (41.3)	2.90	0.089

Bold values denote statistical significance at P < 0.05. The table heading reflects the total N, and the table rows reflect the actual n for each analysis given the missing data.

NH = non-Hispanic. Another race = Asians (n = 8), Native Hawaiians or other Pacific Islanders (n = 3), and those who reported more than one race (n = 52); ^bGovernment insurance = participants who reported having Medicare (n = 171), Medicaid (n = 295), and Military or Verteran’s Affair Insurance (n = 18); ^cHarm perceptions assessed on a scale from 1 (no harm) to 4 (a lot of harm); ^dPositive attitudes about cannabis scores ranged from 0 (strongly disagree) to 4 (strongly agree) based on responses to 3 averaged items: (1) cannabis is not addictive; (2) cannabis is safer to use than prescription pain medications; and (3) cannabis is an effective treatment for general health conditions.

Multivariable logistic regression examining associations among SM status and past 30-day cannabis use, daily/near-daily cannabis use, and CUD symptoms adjusting for sociodemographic covariates are presented in Table 2. SM (vs. heterosexual) females reported greater odds of past 30-day cannabis use and daily/near-daily use, in both crude and adjusted models. Lower harm perceptions, greater positive attitudes toward cannabis, and cannabis marketing exposure were associated with greater odds of past 30-day use. Positive attitudes toward cannabis and cannabis marketing exposure were associated with greater odds of daily/near-daily use. Only greater perceived harm of cannabis use was associated with greater odds of CUD symptoms.

Table 2.

Crude and Adjusted Odds Ratios Predicting Any Past 30-Day Cannabis Use (Among All Females [N = 3020]), Daily/Near-Daily Cannabis Use, and CUD Symptoms (Among Females [N = 985] Who Reported Past 30-Day Cannabis Use).

	Past 30-day cannabis use		Daily/near-daily cannabis use		CUD symptoms
Variables	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 2754)	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 948)	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 948)
Sexual minority	2.75 [2.72, 3.32]	1.95 (1.49, 2.55)	1.66 [1.26, 2.19]	1.47 [1.05, 2.05]	1.27 [0.96, 1.68]	1.28 [0.93, 1.76]
Age (ref: 18-24)
25-34	—	1.45 [1.06, 1.99]	—	1.51 [1.00, 2.27]	—	1.10 [0.75, 1.62]
35-44	—	1.42 [1.01, 2.00]	—	1.77 [1.12, 2.78]	—	0.77 [0.50, 1.19]
45-54	—	1.48 [1.04, 2.12]	—	1.74 [1.06, 2.85]	—	0.84 [0.52, 1.36]
55-64	—	0.77 [0.51, 1.16]	—	1.22 [0.67, 2.20]	—	0.66 [0.37, 1.18]
65+	—	0.41 [0.23, 0.72]	—	2.12 [0.85, 5.27]	—	0.66 [0.26, 1.69]
Race/ethnicity (ref: NH White)
NH Black	—	1.22 [0.81, 1.82]	—	1.43 [0.83, 2.46]	—	2.19 [1.28, 3.78]
NH, another race	—	0.87 [0.64, 1.19]	—	1.33 [0.88, 2.02]	—	1.19 [0.80, 1.77]
Hispanic	—	0.81 [0.54, 1.20]	—	0.67 [0.37, 1.19]	—	1.09 [0.64, 1.86]
Income (ref: less than $20 000)
$20 000-$49 999	—	0.73 [0.56, 0.95]	—	0.65 [0.46, 0.92]	—	0.93 [0.66, 1.30]
$50 000-$99 999	—	0.72 [0.53, 0.99]	—	0.45 [0.29, 0.70]	—	1.00 [0.65, 1.53]
$100 000+	—	0.53 [0.32, 0.89]	—	0.27 [0.12, 0.61]	—	2.36 [1.13, 4.90]
More than bachelor’s degree	—	0.91 [0.67, 1.23]	—	0.50 [0.32, 0.80]	—	0.58 [0.37, 0.91]
Health insurance (ref: private)
Government	—	1.49 [1.14, 1.96]	—	0.98 [0.68, 1.43]	—	1.09 [0.76, 1.56]
No insurance	—	1.83 [1.36, 2.47]	—	0.89 [0.60, 1.33]	—	1.14 [0.77, 1.67]
Medical cannabis license	—	18.81 [14.14, 25.02]	—	3.98 [2.93, 5.41]	—	1.96 [1.46, 2.62]
Age of first cannabis use	—	—	—	0.96 [0.94, 0.98]	—	0.97 [0.95, 0.99]
Cannabis-related factors
Harm perceptions of cannabis use	—	0.72 [0.62, 0.84]	—	0.79 [0.62, 1.01]	—	1.88 [1.48, 2.38]
Positive attitudes toward cannabis	—	2.08 [1.81, 2.38]	—	1.43 [1.18, 1.73]	—	0.90 [0.75, 1.08]
Any cannabis marketing exposure	—	1.96 [1.50, 2.54]	—	1.63 [1.09, 2.42]	—	1.38 [0.93, 2.06]
Depressive symptoms	—	0.96 [0.72, 1.28]	—	0.79 [0.80, 1.01]	—	1.27 [0.89, 1.82]
Anxiety symptoms	—	1.37 [0.99, 1.81]	—	1.29 [0.98, 1.23]	—	1.16 [0.99, 1.22]
Nagelkerke R ²	0.050	0.530	0.017	0.252	0.004	0.166

Bold values denote statistical significance at P < 0.05. With a P-value of <0.001 to correct for multiple comparisons, the following correlates are no longer significant: past 30-day cannabis use: age 25 to 34, 35 to 44, 45 to 54 years, all income variables; daily/near-daily cannabis use: all age groups; CUD symptoms: income $100,000+, more than bachelor’s degree.

Cannabis-Related Factors and Cannabis Use Among Males

Among males, 10.1% identified as SM, 89.9% as heterosexual, and 36.2% reported past 30-day cannabis use (Table 3). A greater percentage of SM (vs. heterosexual) males were younger, reported lower income (i.e., less than $20 000), and were unemployed. A lower percentage of SM males reported having at least a bachelor’s degree. Additionally, a greater percentage of SM (vs. heterosexual) males reported depressive and anxiety symptoms, past 30-day cannabis use, and daily/near-daily cannabis use.

Table 3.

Participant Characteristics and Bivariate Analyses Examining Differences Between Males Identifying as Sexual Minority Versus Heterosexual, n = 2279.

Variables	Total, N = 2279 (100.0%)	Sexual minority, N = 230 (10.1%)	Heterosexual, N = 2049 (89.9%)	χ²/t-statistic	P
Covariates
Age, n (%)	—	—	—	29.75	<0.001
18-24	411 (18.0)	66 (28.7)	345 (16.8)	—	—
25-34	498 (21.9)	60 (26.1)	438 (21.4)	—	—
35-44	581 (25.5)	50 (21.7)	531 (25.9)	—	—
45-54	305 (13.4)	23 (10.0)	282 (13.8)	—	—
55-64	223 (9.8)	17 (7.4)	206 (10.1)	—	—
65+	261 (11.5)	14 (6.1)	247 (12.1)	—	—
Race/ethnicity, n (%)	—	—	—	2.24	0.501
NH White	1581 (69.4)	150 (65.5)	1431 (69.8)	—	—
NH Black	199 (8.7)	25 (10.9)	174 (8.5)	—	—
NH, another race^a	250 (11.0)	28 (12.2)	222 (10.8)	—	—
Hispanic	248 (10.9)	26 (11.4)	222 (10.8)	—	—
Income, n (%)	—	—	—	23.19	<0.001
Less than $20 000	481 (22.0)	72 (33.2)	409 (20.8)	—	—
$20 000-$49 999	652 (29.9)	59 (27.2)	593 (30.1)	—	—
$50 000-$99 999	688 (31.5)	67 (30.9)	621 (31.6)	—	—
$100 000+	363 (16.6)	19 (8.8)	344 (17.5)	—	—
Employment, n (%)	—	—	—	10.54	0.005
Employed full/part-time	1465 (64.3)	128 (55.7)	1337 (65.3)	—	—
Unemployed	248 (10.9)	37 (16.1)	211 (10.3)	—	—
Other	566 (24.8)	65 (28.3)	501 (24.5)	—	—
More than bachelor’s degree, n (%)	696 (23.1)	61 (26.5)	702 (34.3)	5.58	0.018
Health insurance, n (%)	—	—	—	0.38	0.827
Private	879 (38.6)	90 (39.1)	789 (38.5)	—	—
Government^b	911 (40.0)	88 (38.3)	823 (40.2)	—	—
No insurance	488 (21.4)	52 (22.6)	436 (21.3)	—	—
Medical cannabis license, n (%)	546 (24.0)	66 (28.8)	480 (23.4)	3.26	0.071
Age of first cannabis use, M (SD)	18.66 (8.67)	18.12 (8.51)	18.67 (8.62)	0.74	0.458
Cannabis-related factors
Harm perceptions of cannabis use,^c M (SD)	1.97 (1.00)	1.84 (.89)	1.98 (1.00)	1.98	0.101
Positive attitudes toward cannabis,^d M (SD)	3.27 (1.07)	3.33 (1.03)	3.27 (1.07)	−0.82	0.350
Any cannabis marketing exposure, n (%)	1728 (76.0)	174 (76.9)	1552 (75.9)	0.11	0.746
Depressive symptoms, n (%)	547 (24.0)	79 (34.5)	468 (22.9)	15.24	<0.001
Anxiety symptoms, n (%)	558 (24.5)	94 (41.0)	464 (22.7)	37.43	<0.001
Cannabis use and use severity
Any past 30-day use, n (%)	805 (36.2)	100 (45.2)	705 (35.2)	8.68	0.003
Among individuals reporting past 30-day use (n = 805)
Daily/near-daily use, n (%)	401 (49.8)	59 (59.0)	342 (48.5)	3.85	0.049
CUD symptoms, n (%)	471 (58.6)	61 (61.0)	410 (58.2)	0.28	0.600

Bold values denote statistical significance at P < 0.05. The table heading reflects the total N and table rows reflect the actual n for each analysis given missing data.

NH = non-Hispanic. Another race = Asians (n = 5), Native Hawaiians or other Pacific Islanders (n = 5), and those who reported more than one race (n = 55); ^bGovernment insurance = participants who reported having Medicare (n = 219), Medicaid (n = 170), and Military or Verteran’s Affair Insurance (n = 39); ^cHarm perceptions assessed on a scale from 1 (no harm) to 4 (a lot of harm); ^dPositive attitudes about cannabis scores ranged from 0 (strongly disagree) to 4 (strongly agree) based on responses to 3 averaged items: (1) cannabis is not addictive; (2) cannabis is safer to use than prescribed pain medications; and (3) cannabis is an effective treatment for general health conditions.

Multivariable logistic regression (Table 4) indicated that sexual identity was not associated with any past 30-day cannabis use after adjusting for covariates. However, greater positive attitudes toward cannabis, cannabis marketing exposure, depressive symptoms, and lower harm perceptions predicted greater odds of past 30-day use. SM males displayed greater odds of daily/near-daily cannabis use in both crude and adjusted models. Positive attitudes toward cannabis and lower harm perceptions predicted greater odds of daily/near-daily use. Greater harm perceptions, depressive symptoms, and anxiety symptoms predicted greater odds of CUD symptoms, whereas positive attitudes toward cannabis predicted lower odds of CUD symptoms.

Table 4.

Crude and Adjusted Odds Ratios Predicting Any Past 30-Day Cannabis Use (Among All Males [N = 2,279]), Daily/Near-Daily Cannabis Use, and CUD Symptoms (Among Males [N = 805] Who Reported Past 30-Day Cannabis Use).

	Past 30-day cannabis use		Daily/near-daily cannabis use		CUD symptoms
Variables	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 2124)	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 789)	Crude OR, 95% CI	Adjusted OR, 95% CI (N = 789)
Sexual minority	1.52 [1.15, 2.01]	1.35 [0.93, 1.96]	1.53 [1.01, 2.34]	1.92 [1.15, 3.18]	1.12 [0.73, 1.72]	1.28 [0.77, 2.11]
Age (ref: 18-24)
25-34	—	1.30 [0.91, 1.87]	—	1.27 [0.76, 2.12]	—	0.73 [0.44, 1.21]
35-44	—	1.47 [1.02, 2.10]	—	0.94 [0.57, 1.55]	—	0.69 [0.42, 1.14]
45-54	—	1.01 [0.66, 1.54]	—	0.80 [0.42, 1.49]	—	0.48 [0.26, 0.90]
55-64	—	0.70 [0.42, 1.16]	—	1.08 [0.50, 2.33]	—	0.27 [0.12, 0.61]
65+	—	0.42 [0.23, 0.75]	—	1.39 [0.51, 3.75]	—	0.16 [0.06, 0.47]
Race/ethnicity (ref: NH White)	—	—	—	—	—	—
NH Black	—	1.18 [0.78, 1.78]	—	1.03 [0.60, 1.76]	—	1.97 [1.15, 3.38]
NH, another race	—	0.90 [0.61, 1.32]	—	1.09 [0.63, 1.88]	—	1.39 [0.82, 2.37]
Hispanic	—	1.86 [1.28, 2.70]	—	0.69 [0.41, 1.18]	—	1.80 [1.04, 3.10]
Income (ref: less than $20 000)	—		—		—
$20 000-$49 999	—	1.02 [0.74, 1.41]	—	0.87 [0.56, 1.33]	—	1.44 [0.95, 2.18]
$50 000-$99 999	—	0.73 [0.51, 1.05]	—	0.49 [0.29, 0.81]	—	1.92 [1.15, 3.22]
$100 000+	—	1.14 [0.72, 1.79]	—	0.34 [0.17, 0.67]	—	2.01 [1.02, 3.95]
More than bachelor’s degree	—	0.99 [0.73, 1.34]	—	0.56 [0.35, 0.88]	—	1.04 [0.65, 1.66]
Health insurance (ref: private)
Government	—	1.61 [1.20, 2.15]	—	0.98 [0.64, 1.48]	—	1.60 [1.05, 2.44]
No insurance	—	2.21 [1.58, 3.09]	—	1.92 [1.18, 3.13]	—	1.44 [0.90, 2.31]
Medical cannabis license	—	15.10 [11.30, 20.17]	—	3.51 [2.43, 5.07]	—	0.94 [0.66, 1.32]
Age of first cannabis use	—	—	—	0.98 [0.96, 1.00]	—	1.00 [0.98, 1.02]
Cannabis-related factors
Harm perceptions of cannabis use	—	0.74 [0.63, 0.86]	—	0.60 [0.46, 0.76]	—	2.25 [1.69, 2.99]
Positive attitudes toward cannabis	—	1.80 [1.57, 2.06]	—	1.34 [1.09, 1.65]	—	0.79 [0.64, 0.97]
Any cannabis marketing exposure	—	1.78 [1.32, 2.40]	—	0.93 [0.58, 1.50]	—	1.40 [0.89, 2.22]
Depressive symptoms	—	1.35 [1.06, 1.90]	—	0.83 [0.52, 1.32]	—	1.86 [1.18, 2.94]
Anxiety symptoms	—	1.29 [0.92, 1.82]	—	0.96 [0.60, 1.53]	—	1.77 [1.13, 2.76]
Nagelkerke R ²	0.005	0.511	0.006	0.351	0.001	0.291

Bold values denote statistical significance at P < 0.05. With a P-value of <0.001 to correct for multiple comparisons, the following correlates are no longer significant: past 30-day cannabis use: age 35 to 44 years; daily/near-daily cannabis use: more than bachelor’s degree, age of first cannabis use; CUD symptoms: NH Black, Hispanic, all income variables, and government insurance.

Discussion

The current study examined factors (i.e., cannabis-related perceptions, marketing exposure, mental health problems) related to differences in cannabis use and use severity (any past 30-day cannabis use, daily/near-daily cannabis use, CUD symptoms) among SM relative to heterosexual adults residing in Oklahoma. Roughly 18% and 10% of females and males identified as SM, respectively, which is higher than the national and state average.^1,58 A greater proportion of SM females was younger, racially and ethnically diverse, unemployed, uninsured, reported lower education, and had a medical cannabis license relative to heterosexual females. Among SM males, a greater proportion was younger, lower income, unemployed, and reported lower education than heterosexual males. Findings highlight the differences between SM and heterosexual adults in relation to cannabis-related factors, which were associated with cannabis use and use severity.

SM (vs. heterosexual) females reported greater odds of past 30-day cannabis use and daily or near-daily use, consistent with previous literature.^6
-11 SM females also reported lower cannabis-related harm perceptions and a greater percentage reported cannabis marketing exposure, depressive symptoms, and anxiety symptoms relative to heterosexual females. In contrast, SM males were more likely than heterosexual males to report daily or near-daily cannabis use in both crude and adjusted models, but were not more likely to report any past 30-day cannabis use after adjusting for other factors. While SM males displayed higher rates of depressive and anxiety symptoms relative to heterosexual males, they showed no differences in other factors.

Neither SM females nor SM males displayed greater odds of CUD symptoms relative to heterosexual individuals. While SM individuals report that cannabis helps to alleviate depressive symptoms, they also report concerns about developing CUD symptoms.⁵⁹ Thus, participants in the current study may have been using cannabis at elevated rates, but are mindful about the possibility of developing CUD symptoms. Interestingly, greater harm perceptions were associated with greater odds of CUD symptoms among both females and males, potentially suggesting that individuals with CUD symptoms are more likely to perceive cannabis as harmful once they have become dependent. However, future work exploring these phenomena is warranted.

Findings expand upon limited work regarding a range of factors that are related to cannabis use among SM relative to heterosexual individuals, including cannabis-related marketing exposure³⁴ and harm perceptions.²⁶ They are consistent with those found among adolescent and young adult samples^34,35 and found in the tobacco literature,^60,61 which demonstrate that SM young adults report greater tobacco marketing exposure due to targeted marketing efforts from the tobacco industry (e.g., at LGBTQ+ community events). SM females’ lower cannabis-related harm perceptions relative to heterosexual females may be due to multiple factors, including: (a) higher rates of recent cannabis marketing exposure (as marketing efforts often include health claims and few health warnings^62
-64), particularly in places like Oklahoma with high levels of cannabis marketing exposure^43,44; and (b) greater use within LGBTQ+ social networks, which may impact risk perceptions via social norms.^65,66

Cannabis marketing exposure and lower cannabis harm perceptions were associated with greater odds of any past 30-day cannabis use and daily or near-daily cannabis use among females. Individuals with lower cannabis-related harm perceptions likely worry less about adverse effects of cannabis (e.g., mental health problems), leading to greater likelihood of current use.⁶⁷ Greater exposure to cannabis-related marketing is also associated with greater purchasing access (e.g., via dispensaries, online) and cannabis availability.^37,40,41,68 Indeed, almost twice the proportion of SM females compared to heterosexual females in our sample reported having a current medical cannabis license. Findings are also consistent with the tobacco literature, which suggests that SM females are more receptive to tobacco marketing than heterosexual females.^32,61

Greater proportions of SM females and males reported depressive and anxiety symptoms relative to their heterosexual peers. However, neither depressive nor anxiety symptoms were associated with cannabis use outcomes among females after accounting for other factors. Among males, depressive symptoms were associated with greater odds of past 30-day cannabis use. From the lens of Minority Stress Theory, results may be emblematic of multiple community-level factors, including experiencing discrimination and marginalization across multiple social institutions (e.g., families, peers, workplace, society) and residing in an unsupportive state policy context, driving depressive symptoms and, in turn, using compensatory cannabis to self-soothe from these stressors.^69,70

Current findings have implications for future research, policy, and practice. Findings stress the importance of moving beyond the Minority Stress Model to identify additional correlates of SM cannabis use differences, such as industry-level influences (e.g., cannabis marketing and related harm perceptions). Future research should examine how and why SM females are more frequently exposed to cannabis marketing than non-SM, including whether cannabis industries are engaging in targeted marketing to these groups like the tobacco industry.^29,71 Moreover, research examining the influences of cannabis-related social norms and social meanings of cannabis on cannabis use and use severity among SM groups is needed.

Cannabis prevention messaging and cessation efforts should be tailored toward SM females and males, respectively, given different correlates of cannabis use among these groups relative to their heterosexual peers. Public health campaigns addressing cannabis-related harms may most effectively reach SM females in Oklahoma, whereas interventions focused on mental health symptoms along with the social conditions that perpetuate stigma and discrimination related to sexual identity may be most effective in reaching SM males in Oklahoma. We are unable to determine whether SM males and females in our sample were differentially exposed to cannabis-related targeted marketing, but this should be examined in future studies.

Limitations

The current study had several limitations. First, nearly one-third of our sample reported past 30-day cannabis use, which is higher than the 2019 to 2020 prevalence rate for Oklahoma (14.2%).⁵⁸ However, this could be because we asked respondents about both their medical and recreational cannabis use. Given limitations on recruiting such a large sample in Oklahoma, the sample was not fully representative of the state, although our demographics for age, sex, race/ethnicity, income, and insurance aligned with state estimates (within 3%-5%).⁷² Because this study was conducted only in Oklahoma, findings should not be generalized to other states with varying legalized cannabis contexts. Second, the data were self-reported and cross-sectional, potentially leading to shared method variance and preventing our ability to examine causal or bidirectional associations among cannabis-related factors and cannabis use. Third, all SM females and males, respectively, were combined into a single group to increase sample size when making comparisons by cannabis-related factors and behaviors. Prior research has identified differences within the SM community (e.g., bisexual females have higher rates of substance use than lesbian females⁷³). Fourth, gender identity was not examined in the current study. Future research should examine patterns of cannabis-related factors and behaviors among specific SM-by-gender subgroups of adults. Finally, use of the PHQ-2, GAD-2, and CUDIT-SF prevented us from capturing a clinical diagnosis of depression, anxiety, or CUD.

Conclusions

The current study examined differences in a range of potential cannabis-related factors and behaviors among SM and heterosexual adults in Oklahoma. SM (vs. heterosexual) females reported higher rates of cannabis use, whereas SM (vs. heterosexual) females and males reported higher rates of daily/near-daily cannabis use. Among females, findings may be related to cannabis marketing exposure (for past 30-day and daily/near-daily use) and harm perceptions (past 30-day use), whereas past 30-day cannabis use among males may be related to depressive symptoms. With future replication, findings highlight important potential targets for reducing cannabis-related disparities among SM, relative to heterosexual females and males, respectively, living in places with legal medical cannabis retail markets, high structural stigma, and pronounced substance use. Public health campaigns aimed at correcting misinterpretations of harm that could emanate from marketing efforts by the cannabis industry may help reduce cannabis use among SM females, whereas SM males may be better reached by intervention efforts targeting mental health symptoms, as well as large-scale interventions that attend to the unjust social conditions that perpetuate stigma and discrimination related to sexual identity.

Footnotes

Author Contributions

All authors contributed to the conceptualization of the study and reviewed the article drafts. Data analyses were conducted by KFR. Initial article drafts were led by KFR and AMC.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this publication was supported in part by the National Cancer Institute Cancer Center Support Grant P30CA225520 awarded to the University of Oklahoma Stephenson Cancer Center, a seed grant awarded to AMC from the Oklahoma Tobacco Settlement Endowment Trust Contract # R22-03, and a career development award (K01DA055073) awarded to EAV from the National Institute on Drug Abuse. The content is solely the responsibility of the research team and does not necessarily represent the official views of the National Institutes of Health.

Compliance,Ethical Standards,and Ethical Approval

Institutional Review Board approvals were obtained from University of Oklahoma Health Sciences Center.

ORCID iD

Katelyn F. Romm

References

Jones

. LGBT identification in U.S. Ticks Up to 7.1%. 2022. Accessed February 1, 2023. https://news.gallup.com/poll/389792/lgbt-identification-ticks-up.aspx

NASEM. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press; 2017. doi:10.17226/24625

Memedovich

Dowsett

Spackman

Noseworthy

Clement

The adverse health effects and harms related to marijuana use: an overview review. CMAJ Open. 2018;6(3):E339-e346. doi:10.9778/cmajo.20180023

Agrawal

Lynskey

Bucholz

, et al. DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend. 2014;134:362-369. doi:10.1016/j.drugalcdep.2013.11.008

Connor

Stjepanović

Le Foll

Hoch

Budney

Hall

WD.

Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16. doi:10.1038/s41572-021-00247-4

Medley

Lipari

Bose

Cribb

Kroutil

McHenry

(2016) Sexual orientation and estimates of adult substance use and mental health: Results from the 2015 national survey on drug use and health. Accessed February 1, 2023. https://www.samhsa.gov/data/

SAMHSA (2018) Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. Accessed February 1, 2023. https://www.samhsa.gov/data/sites/default/files/cbhsqreports/NSDUHFFR2017/NSDUHFFR2017.pdf

Gonzales

Differences in 30-day marijuana use by sexual orientation identity: population-based evidence from seven states. LGBT Health. 2020;7(1):60-67. doi:10.1089/lgbt.2018.0236

Mantey

Yockey

Lee

JGL

. Sexual minority status and marijuana initiation during adulthood: a longitudinal study using nationally representative data. Subst Use Misuse. 2021;56(7):1054-1061. doi:10.1080/10826084.2021.1906704

10.

Boyd

Veliz

McCabe

SE.

Severity of DSM-5 cannabis use disorders in a nationally representative sample of sexual minorities. Subst Abus. 2020;41(2):191-195. doi:10.1080/08897077.2019.1621242

11.

Ehlke

Kendzor

Smith

Sifat

Boozary

Cohn

AM.

Single-use, co-use, and polysubstance use of alcohol, tobacco, and cannabis in sexual minority and heterosexual females. Am J Addict. 2022;32:66–75. doi:10.1111/ajad.13344

12.

Kendzor

Ehlke

Kharazi Boozary

Smith

Cohn

AM.

Characteristics of adults with a medical cannabis license, reasons for use, and perceptions of benefit following medical cannabis legalization in Oklahoma. Prev Med Rep. 2022;27:101777. doi:10.1016/j.pmedr.2022.101777

13.

Drabble

Mericle

Gómez

Klinger

Trocki

Karriker-Jaffe

KJ.

Differential effects of state policy environments on substance use by sexual identity: findings from the 2000-2015 national alcohol surveys. Ann LGBTQ Public Popul Health. 2021;2(1):53-71. doi:10.1891/lgbtq-2020-0029

14.

SAMHSA. 2018 National survey on drug use and health: lesbian, gay, & bisexual (LGB) adults (annual report). 2018. Accessed February 1, 2023. https://www.samhsa.gov/data/report/2018-nsduh-lesbiangay-bisexual-lgb-adults.

15.

McCabe

Hughes

Bostwick

West

Boyd

CJ.

Sexual orientation, substance use behaviors and substance dependence in the United States. Addiction. 2009;104(8):1333-1345. doi:10.1111/j.1360-0443.2009.02596.x

16.

Trocki

Drabble

Midanik

LT.

Tobacco, marijuana, and sensation seeking: comparisons across gay, lesbian, bisexual, and heterosexual groups. Psychol Addict Behav. 2009;23(4):620-631. doi:10.1037/a0017334

17.

Bonn-Miller

Heinz

Smith

Bruno

Adamson

Preliminary development of a brief cannabis use disorder screening tool: the cannabis use disorder identification test short-form. Cannabis Cannabinoid Res. 2016;1(1):252-261. doi:10.1089/can.2016.0022

18.

Meyer

Frost

Minority stress and the health of sexual minorities. In: Patterson

D’Augelli

, eds. Handbook of Psychology and Sexual Orientation. Oxford University Press;2013:252–266. doi:10.1093/acprof:oso/9780199765218.003.0018

19.

Meyer

IH.

Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull. 2003;129(5):674-697. doi:10.1037/0033-2909.129.5.674

20.

Hatzenbuehler

ML.

How does sexual minority stigma “get under the skin”? A psychological mediation framework. Psychol Bull. 2009;135(5):707-730. doi:10.1037/a0016441

21.

Krueger

Fish

Upchurch

DM.

Sexual orientation disparities in substance use: investigating social stress mechanisms in a national sample. Am J Prev Med. 2020;58(1):59-68. doi:10.1016/j.amepre.2019.08.034

22.

Lee

Gamarel

Bryant

Zaller

Operario

Discrimination, mental health, and substance use disorders among sexual minority populations. LGBT Health. 2016;3(4):258-265. doi:10.1089/lgbt.2015.0135

23.

Hatzenbuehler

Jun

Corliss

Bryn Austin

Structural stigma and sexual orientation disparities in adolescent drug use. Addict Behav. 2015;46:14-18. doi:10.1016/j.addbeh.2015.02.017

24.

Drydakis

The perceived social rejection of sexual minorities: substance use and unprotected sexual intercourse. Drug Alcohol Rev. 2022;41(6):1341-1354. doi:10.1111/dar.13500

25.

Goldbach

Schrager

Dunlap

Holloway

IW.

The application of minority stress theory to marijuana use among sexual minority adolescents. Subst Use Misuse. 2015;50(3):366-375. doi:10.3109/10826084.2014.980958

26.

Schuler

Evans-Polce

RJ.

Perceived substance use risks among never users: sexual identity differences in a sample of U.S. young adults. Am J Prev Med. 2022;63(6):987-996. doi:10.1016/j.amepre.2022.07.003

27.

Azagba

Shan

Exposure to tobacco and e-cigarette advertisements by sexual identity status among high school students. Addict Behav. 2022;125:107165. doi:10.1016/j.addbeh.2021.107165

28.

Soneji

Knutzen

Tan

ASL

, et al. Online tobacco marketing among US adolescent sexual, gender, racial, and ethnic minorities. Addict Behav. 2019;95:189-196. doi:10.1016/j.addbeh.2019.03.015

29.

Stevens

Carlson

Hinman

JM.

An analysis of tobacco industry marketing to lesbian, gay, bisexual, and transgender (LGBT) populations: strategies for mainstream tobacco control and prevention. Health Promot Pract. 2004;5(3 Suppl):129s-134s. doi:10.1177/1524839904264617

30.

Smith

Malone

RE.

The outing of Philip Morris: advertising tobacco to gay men. Am J Public Health. 2003;93(6):988-993. doi:10.2105/ajph.93.6.988

31.

Smith

Offen

Malone

RE.

What makes an ad a cigarette ad? Commercial tobacco imagery in the lesbian, gay, and bisexual press. J Epidemiol Community Health. 2005;59(12):1086-1091. doi:10.1136/jech.2005.038760

32.

Dilley

Spigner

Boysun

Dent

Pizacani

BA.

Does tobacco industry marketing excessively impact lesbian, gay and bisexual communities?

Tob Control. 2008;17(6):385-390. doi:10.1136/tc.2007.024216

33.

Struble

Bauer

Lundahl

Ghosh

Ledgerwood

DM.

Electronic cigarette use among sexual minority and heterosexual young adults in a U.S. national sample: exploring the modifying effects of advertisement exposure. Prev Med. 2022;155:106926. doi:10.1016/j.ypmed.2021.106926

34.

Fiala

Dilley

Everson

Firth

Maher

JE.

Youth exposure to marijuana advertising in oregon’s legal retail marijuana market. Prev Chronic Dis. 2020;17:E110. doi:10.5888/pcd17.190206

35.

Krueger

Bello

Unger

, et al. Sociodemographic differences in young adults’ recall of tobacco and cannabis marketing online and in television/film. Prev Med Rep. 2021;24:101592. doi:10.1016/j.pmedr.2021.101592

36.

Whitehill

Trangenstein

Jenkins

Jernigan

Moreno

MA.

Exposure to cannabis marketing in social and traditional media and past-year use among adolescents in states with legal retail cannabis. J Adolesc Health. 2020;66(2):247-254. doi:10.1016/j.jadohealth.2019.08.024

37.

Dai

Exposure to advertisements and marijuana use among US adolescents. Prev Chronic Dis. 2017;14:E124. doi:10.5888/pcd14.170253

38.

D’Amico

Miles

Tucker

JS.

Gateway to curiosity: medical marijuana ads and intention and use during middle school. Psychol Addict Behav. 2015;29(3):613-619. doi:10.1037/adb0000094

39.

Krauss

Sowles

Sehi

, et al. Marijuana advertising exposure among current marijuana users in the U.S. Drug Alcohol Depend. 2017;174:192-200. doi:10.1016/j.drugalcdep.2017.01.017

40.

Rup

Goodman

Hammond

Cannabis advertising, promotion and branding: differences in consumer exposure between “legal” and “illegal” markets in Canada and the US. Prev Med. 2020;133:106013. doi:10.1016/j.ypmed.2020.106013

41.

Lipperman-Kreda

Islam

Wharton

Finan

Kowitt

SD.

Youth tobacco and cannabis use and co-use: associations with daily exposure to tobacco marketing within activity spaces and by travel patterns. Addict Behav. 2022;126:107202. doi:10.1016/j.addbeh.2021.107202

42.

Mallory

Vasquez

Brown

TNT

Momen

Sears

The impact of stigma and discrimination against LGBT people in West Virginia. 2021. Accessed February 1, 2023. https://williamsinstitute.law.ucla.edu/wp-content/uploads/Impact-LGBT-Discrimination-WV-Feb-2021.pdf

43.

Francis-Smith

‘Astonishing’: state leads nation in number of cannabis dispensaries. J Rec. Published online February 5, 2020. https://journalrecord.com/2020/02/05/astonishing-state-leads-nation-in-number-of-cannabis-dispensaries/

44.

Cohn

Alexander

Ehlke

, et al. Seeing is believing: how cannabis marketing exposure is associated with cannabis use attitudes and behavior in a permissive medical cannabis policy environment. Am J Addict. 2023;32:333-342. doi:10.1111/ajad.13390

45.

Pachankis

Hatzenbuehler

Starks

TJ.

The influence of structural stigma and rejection sensitivity on young sexual minority men’s daily tobacco and alcohol use. Soc Sci Med. 2014;103:67-75. doi:10.1016/j.socscimed.2013.10.005

46.

Phillips

. Data shows discrimination is a clear barrier to the success of LGBTQ2S+ Oklahomans. 2022. Accessed February 1, 2023. https://okpolicy.org/data-shows-discrimination-is-a-clear-barrier-to-thesuccess-of-lgbtq2s-oklahomans/.

47.

Daniller

. Two-thirds of Americans support marijuana legalization. 2019. Accessed February 1, 2023. https://www.pewresearch.org/fact-tank/2019/11/14/americans-support-marijuana-legalization/

48.

US Census Bureau. US census bureau quick facts: Oklahoma 2017-2021. 2022. Accessed August 30, 2023. https://www.census.gov/quickfacts/fact/table/OK/PST045222

49.

Kroenke

Spitzer

Williams

JB.

The patient health questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. doi:10.1097/01.Mlr.0000093487.78664.3c

50.

Skapinakis

The 2-item generalized anxiety disorder scale had high sensitivity and specificity for detecting GAD in primary care. Evid Based Med. 2007;12(5):149. doi:10.1136/ebm.12.5.149

51.

Compton

Han

Jones

Blanco

Hughes

Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3(10):954-964. doi:10.1016/s2215-0366(16)30208-5

52.

Martins

Segura

Levy

, et al. Racial and ethnic differences in cannabis use following legalization in US states with medical cannabis laws. JAMA Netw Open. 2021;4(9):e2127002. doi:10.1001/jamanetworkopen.2021.27002

53.

Patrick

Wightman

Schoeni

Schulenberg

JE.

Socioeconomic status and substance use among young adults: a comparison across constructs and drugs. J Stud Alcohol Drugs. 2012;73(5):772-782. doi:10.15288/jsad.2012.73.772

54.

Thompson

Leadbeater

Ames

Merrin

GJ.

Associations between marijuana use trajectories and educational and occupational success in young adulthood. Prev Sci. 2019;20(2):257-269. doi:10.1007/s11121-018-0904-7

55.

Hawke

Wilkins

Henderson

Early cannabis initiation: substance use and mental health profiles of service-seeking youth. J Adolesc. 2020;83:112-121. doi:10.1016/j.adolescence.2020.06.004

56.

Baumeister

Tossmann

Association between early onset of cigarette, alcohol and cannabis use and later drug use patterns: an analysis of a survey in European metropolises. Eur Addict Res. 2005;11(2):92-98. doi:10.1159/000083038

57.

Silins

Horwood

Patton

, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286-293. doi:10.1016/s2215-0366(14)70307-4

58.

SAMHSA. Oklahoma—national survey on drug abuse and health: 2019-2020. 2022. Accessed February 1, 2023. https://www.samhsa.gov/data/sites/default/files/reports/rpt35964/NSDUHHsaeSpecificStates2020F/NSUHsaeOklahoma2020.pdf

59.

Parent

Coulaud

Amirie

Ferlatte

Knight

Cannabis use and mental health among young sexual and gender minority men: a qualitative study. Int J Drug Policy. 2021;91:102980. doi:10.1016/j.drugpo.2020.102980

60.

Acosta-Deprez

Jou

London

, et al. Tobacco control as an LGBTQ+ issue: knowledge, attitudes, and recommendations from LGBTQ+ community leaders. Int J Environ Res Public Health. 2021;18(11):5546. doi:10.3390/ijerph18115546

61.

Tan

ASL

Hanby

Sanders-Jackson

Lee

Viswanath

Potter

. Inequities in tobacco advertising exposure among young adult sexual, racial and ethnic minorities: examining intersectionality of sexual orientation with race and ethnicity. Tob Control. 2021;30(1):84-93. doi:10.1136/tobaccocontrol-2019-055313

62.

Cavazos-Rehg

Krauss

Cahn

, et al. Marijuana promotion online: an investigation of dispensary practices. Prev Sci. 2019;20(2):280-290. doi:10.1007/s11121-018-0889-2

63.

Berg

Henriksen

Cavazos-Rehg

Schauer

Freisthler

The development and pilot testing of the marijuana retail surveillance tool (MRST): assessing marketing and point-of-sale practices among recreational marijuana retailers. Health Educ Res. 2017;32(6):465-472. doi:10.1093/her/cyx071

64.

Berg

Henriksen

Cavazos-Rehg

Schauer

Freisthler

Point-of-sale marketing and context of marijuana retailers: assessing reliability and generalizability of the marijuana retail surveillance tool. Prev Med Rep. 2018;11:37-41. doi:10.1016/j.pmedr.2018.05.010

65.

Boyle

LaBrie

Omoto

AM.

Normative substance use antecedents among sexual minorities: a scoping review and synthesis. Psychol Sex Orientat Gend Divers. 2020;7(2):117-131. doi:10.1037/sgd0000373

66.

Boyle

LaBrie

Costine

Witkovic

YD.

“It’s how we deal”: perceptions of LGB peers’ use of alcohol and other drugs to cope and sexual minority adults’ own coping motivated substance use following the Pulse nightclub shooting. Addict Behav. 2017; 65: 51-55. doi:10.1016/j.addbeh.2016.10.001

67.

Gali

Winter

Ahuja

Frank

Prochaska

JJ.

Changes in cannabis use, exposure, and health perceptions following legalization of adult recreational cannabis use in California: a prospective observational study. Subst Abuse Treat Prev Policy. 2021;16(1):16. doi:10.1186/s13011-021-00352-3

68.

Trangenstein

Whitehill

Jenkins

Jernigan

Moreno

MA.

Cannabis marketing and problematic cannabis use among adolescents. J Stud Alcohol Drugs. 2021;82(2):288-296. doi:10.15288/jsad.2021.82.288

69.

Sarvet

Wall

Keyes

Olfson

Cerdá

Hasin

DS.

Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws. Drug Alcohol Depend. 2018;186:10-15. doi:10.1016/j.drugalcdep.2018.01.009

70.

Smith

Yan

Charles

, et al. Exploring the link between substance use and mental health status: what can we learn from the self-medication theory? J Health Care Poor Underserved. 2017;28(2s):113-131. doi:10.1353/hpu.2017.0056

71.

Smith

Thomson

Offen

Malone

RE.

“If you know you exist, it’s just marketing poison”: meanings of tobacco industry targeting in the lesbian, gay, bisexual, and transgender community. Am J Public Health. 2008;98(6):996-1003. doi:10.2105/ajph.2007.118174

72.

US Census Bureau. Annual county resident population estimates by age, sex, race, and hispanic origin: april 2010 to July 1, 2020. 2020. Accessed August 30, 2023. https://www.census.gov/newsroom/press-kits/2020/population-estimates-detailed.html

73.

Schuler

Collins

RL.

Sexual minority substance use disparities: bisexual women at elevated risk relative to other sexual minority groups. Drug Alcohol Depend. 2020;206:107755.

Cannabis Use Differences Among Sexual Minority Versus Heterosexual Females and Males in Oklahoma: The Roles of Mental Health,Cannabis Perceptions,and Cannabis Marketing Exposure

Abstract

Introduction:

Methods:

Results:

Conclusions:

Keywords

Highlights

Introduction

Methods

Participants and Procedures

Measures

Covariates

Sexual Identity by Sex Subgroup

Cannabis-Related Factors

Cannabis Use and Use Severity

Data Analysis

Results

Cannabis-Related Factors and Cannabis Use Among Females

Cannabis-Related Factors and Cannabis Use Among Males

Discussion

Limitations

Conclusions

Footnotes

Author Contributions

Declaration of Conflicting Interests

Funding

Compliance,Ethical Standards,and Ethical Approval

ORCID iD

References